Chemistry: analytical and immunological testing – Biospecific ligand binding assay
Reexamination Certificate
2006-10-12
2009-11-03
Yu, Misook (Department: 1642)
Chemistry: analytical and immunological testing
Biospecific ligand binding assay
C436S518000, C435S007100, C435S007230
Reexamination Certificate
active
07611904
ABSTRACT:
Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (SIX Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.
REFERENCES:
patent: 5416064 (1995-05-01), Chari et al.
patent: 5859045 (1999-01-01), Treppendahl et al.
patent: 6048970 (2000-04-01), Lal et al.
patent: 6329503 (2001-12-01), Afar et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6887975 (2005-05-01), Afar et al.
patent: 7053186 (2006-05-01), Afar et al.
patent: 7166714 (2007-01-01), Afar et al.
patent: 2002/0022248 (2002-02-01), Xu et al.
patent: 2003/0045682 (2003-03-01), Afar et al.
patent: 2003/0060612 (2003-03-01), Goddard et al.
patent: 2003/0064397 (2003-04-01), Spancake et al.
patent: 0834563 (1998-04-01), None
patent: WO 94/09150 (1994-04-01), None
patent: WO 98/18489 (1998-05-01), None
patent: WO 98/37093 (1998-08-01), None
patent: WO 98/37418 (1998-08-01), None
patent: WO 98/53071 (1998-11-01), None
patent: WO 99/06548 (1999-02-01), None
patent: WO 99/06550 (1999-02-01), None
patent: WO 99/61469 (1999-02-01), None
patent: WO 99/62941 (1999-12-01), None
patent: WO 00/04149 (2000-01-01), None
patent: WO 00/35937 (2000-06-01), None
patent: WO 01/12662 (2001-02-01), None
patent: WO 01/72962 (2001-10-01), None
patent: WO 02/16429 (2002-02-01), None
patent: WO 02/26822 (2002-04-01), None
patent: WO 2005/113601 (2005-12-01), None
patent: WO 03/022995 (2006-03-01), None
patent: WO 2006/034488 (2006-03-01), None
Challita-Eid Pia M., et al., “Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo”, vol. 67, No. 12, pp. 5798-5805, (2007).
Faris M., et al., “Validation of STEAP-1 as a cell surface cancer therapeutic target”, Proceedings of the annual meeting of the American Association for Cancer Research, vol. 43, p. 947, (2002).
Abu-Threideh et al., Jun. 1998, EMBL/GENBAK/DDBJ Databases.
Abu-Threideh et al., GENBANK (Accession No. 095034) National Library of Medicine, Bethesda MD, May 1, 1999.
Alberts et al., Molecular Biology of the Cell, 3rdedition (1994) p. 465.
Bellone et al., Immunolgoy Today (1999) 20(10):457-462.
Bowie et al, Science 247:1306-1310 (1990).
Burgess et al., J. Cell Biol. 111:2129-2138 (1990).
Cate et al., GENBANK (Accession No. W86309) National Library of Medicine, Bethesda MD, Nov. 1998.
Database EMBL Nucleotide and Protein Sequences, Aug. 25, 1996, XP002128081, AA032221, Hinxton, GB.
Database EMBL Nucleotide and Protein Sequences, May 13, 1997, XP002128082, AC002064, Hinxton, GB.
Database EMBL Nucleotide and Protein Sequences, Jun. 15, 1998, XP002128084, AC004969 (clone DJ112E10), Hinxton, GB.
Database EMBL, “Human BAC Clone CTB-167B5 form 7q21, complete sequence,”, Jun. 17, 1998, XP002173859, AC003991, R. Waterston et al.
Database EMBL Nucleotide and Protein Sequences, May 1, 1999, XP002128083, O95034 (clone RG041D11), Hinxton, GB.
Diss et al., “Expression of skeletal muscle-type voltage-gated Na+ channel in rat and human prostate cancer cell lines,” FEBS Letters 427:5-10 (1998).
Dulcert et al., GENBANK (Accession No. Y11840), National Library of Medicine, Bethesda MD, Feb. 11, 1999.
Fu et al., EMBO Journal 15:4392-4401 (1996).
Greenspan et al, Nature Biotechnology 7:936-937 (1999).
Grimes et al., “Electrophysiological characterization of voltage-gated NA+ current expressed in the highly metastatic Mat-LyLu cell line of rat prostate cancer,” Journal of Cellular Physiology 175:50-58 (1998).
Gutierrrez et al., “Activation of a Ca2+-permeable cation channel by two different inducers of apoptosis in a human prostatic cancer cell line,” Journal of Physiology 517:95-107 (1999).
Gura, Science 278:1041-1042 (1997).
Haverstick et al., “Inhibition of human prostate cancer proliferation in vitro and in a mouse model by a compound synthesized to block Ca2+entry,” Cancer Research pp. 1002-1008 (2000).
Herbert et al., The Dictionary of Immunology, Academic Press, 4thedition (1995).
Hubert et al., PNAS USA 96(25):14523-14528 (1999).
Lazar et al., Mol Cell. Biol. 8(3):1247-1252 (1988).
Lepple-Weinhues et al., “K+ channels and the intracellular calcium signal in human melanoma cell proliferation,” J. Membrane Biol. 151:149-157 (1996).
Marino et al., “Association between cell membrane potential and breast cancer,” Tumor Biol. 15:82-89 (1994).
McClean et al., Eur. J. of Cancer 29A:2243-2248 (1993).
Nie et al., “Inhibition of proliferation of MCF-7 breast cancer cells by a blocker of Ca2+-permeable channel,” Celll Calcium 22(2):75-82 (1997).
Pancrazio et al., “Voltage-dependent ion channels in small-cell lung cancer cells,” Cancer Research 49:5901-5906 (1989).
Reiger et al., Glossary of Genetics and Cytogenetics, Springer-Verlag (1976), p. 17.
Shantz et al., Int. J. Biochem. Cell Bio. 31:107-122 (1999).
Skryma et al., “Potassium conductance in the androgen-sensitive prostate cancer cell line, LNCaP: involvement in cell proliferation,” The Prostate 33:112-122 (1997).
Spitler, Cancer Biotherapy 10:1-3 (1995).
Afar Daniel E.
Hubert Rene S.
Leong Kahan
Mitchell Stephen Chappell
Raitano Arthur B.
Agarwal Atulya
Agensys, Inc.
Dreger Ginger R.
Popp, J.D., L.L.M. Shane M.
Yu Misook
LandOfFree
Serpentine transmembrane antigens expressed in human cancers... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Serpentine transmembrane antigens expressed in human cancers..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Serpentine transmembrane antigens expressed in human cancers... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4076873